At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
In Brief
A Phase 2 clinical trial evaluating Tenofovir Alafenamide, VIR-2218, and 2 other interventions for Chronic Hepatitis B. Completed, enrolled 103 participants across 26 sites in 8 countries.
Detailed Summary
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(s) as measured by the proportion of participants who achieve functional cure, defined as hepatitis B surface antigen (HBsAg) loss and hepatitis B virus (HBV)deoxyribonucleic acid (DNA) \< lower limit of quantitation (LLOQ) at Follow-up (FU) Week 24 in participants with chronic hepatitis B (CHB).
Study Details
Timeline
Interventions
Administered as film-coated oral tablets
Administered as a sub-cutaneous (SC) injection
Administered intravenously
Administered as film-coated oral tablets